Chavez-Tapia Norberto C, Soares-Weiser Karla, Brezis Mayer, Leibovici Leonard
Department of Gastroenterology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Vasco de Quiroga #5, Mexico City, Distrito Federal, Mexico, 14000.
Cochrane Database Syst Rev. 2009 Jan 21;2009(1):CD002232. doi: 10.1002/14651858.CD002232.pub2.
Spontaneous bacterial peritonitis is a complication of cirrhotic ascites that occurs in the absence of any intra-abdominal, surgically treatable source of infection. Antibiotic therapy is indicated and should be initiated as soon as possible to avoid severe complications that may lead to death. It has been proposed that empirical treatment should cover gram-negative enteric bacteria and gram-positive cocci, responsible for up to 90% of spontaneous bacterial peritonitis cases.
This review aims to evaluate the beneficial and harmful effects of different types and modes of antibiotic therapy in the treatment of spontaneous bacterial peritonitis in cirrhotic patients.
We performed electronic searches in The Cochrane Hepato-Biliary Group Controlled Trials Register (July 2008), the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library (Issue 3, 2008), MEDLINE (1950 to July 2008), EMBASE (1980 to July 2008), and Science Citation Index EXPANDED (1945 to July 2008). In addition, we handsearched the references of all identified studies and contacted the first author of each included trial.
Randomised studies comparing different types of antibiotics for spontaneous bacterial peritonitis in cirrhotic patients.
Data were independently extracted from the trials by at least two authors. Peto odds ratios or average differences, with their 95% confidence intervals, were estimated.
This systematic review attempted to summarise evidence from randomised clinical trials on the treatment of spontaneous bacterial peritonitis. Thirteen studies were included; each one of them compared different antibiotics in their experimental and control groups. No meta-analyses could be performed, though data on the main outcomes were collected and analysed separately for each included trial. Currently, the evidence showing that lower dosage or short-term treatment with third generation cephalosporins is as effective as higher dosage or long-term treatment is weak. Oral quinolones could be considered an option for those with less severe manifestations of the disease.
AUTHORS' CONCLUSIONS: This review provides no clear evidence for the treatment of cirrhotic patients with spontaneous bacterial peritonitis. In practice, third generation cephalosporins have already been established as the standard treatment of spontaneous bacterial peritonitis, and it is clear, that empirical antibiotic therapy should be provided in any case. However, until large, well-conducted trials provide more information, practice will remain based on impression, not evidence.
自发性细菌性腹膜炎是肝硬化腹水的一种并发症,发生时不存在任何可通过手术治疗的腹腔内感染源。需要进行抗生素治疗,且应尽快开始,以避免可能导致死亡的严重并发症。有人提出,经验性治疗应覆盖革兰氏阴性肠道细菌和革兰氏阳性球菌,这两种细菌导致了高达90%的自发性细菌性腹膜炎病例。
本综述旨在评估不同类型和方式的抗生素治疗对肝硬化患者自发性细菌性腹膜炎的有益和有害影响。
我们在Cochrane肝胆组对照试验注册库(2008年7月)、Cochrane图书馆中的Cochrane对照试验中央注册库(CENTRAL,2008年第3期)、MEDLINE(1950年至2008年7月)、EMBASE(1980年至2008年7月)以及科学引文索引扩展版(1945年至2008年7月)中进行了电子检索。此外,我们还手工检索了所有已识别研究的参考文献,并联系了每个纳入试验的第一作者。
比较不同类型抗生素治疗肝硬化患者自发性细菌性腹膜炎的随机研究。
数据由至少两名作者独立从试验中提取。估计了Peto比值比或平均差异及其95%置信区间。
本系统综述试图总结关于自发性细菌性腹膜炎治疗的随机临床试验证据。纳入了13项研究;每项研究在实验组和对照组中比较了不同的抗生素。虽然收集了主要结局的数据并对每个纳入试验分别进行了分析,但无法进行荟萃分析。目前,关于低剂量或短期使用第三代头孢菌素与高剂量或长期使用同样有效的证据不足。对于病情较轻的患者,口服喹诺酮类药物可被视为一种选择。
本综述未提供关于治疗肝硬化患者自发性细菌性腹膜炎的明确证据。在实践中,第三代头孢菌素已被确立为自发性细菌性腹膜炎的标准治疗方法,而且很明显,在任何情况下都应提供经验性抗生素治疗。然而,在大型、设计良好的试验提供更多信息之前,实践仍将基于经验而非证据。